Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TRASTUZUMAB Cause C-reactive protein increased? 173 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 173 reports of C-reactive protein increased have been filed in association with TRASTUZUMAB (Trazimera). This represents 0.4% of all adverse event reports for TRASTUZUMAB.

173
Reports of C-reactive protein increased with TRASTUZUMAB
0.4%
of all TRASTUZUMAB reports
28
Deaths
135
Hospitalizations

How Dangerous Is C-reactive protein increased From TRASTUZUMAB?

Of the 173 reports, 28 (16.2%) resulted in death, 135 (78.0%) required hospitalization, and 8 (4.6%) were considered life-threatening.

Is C-reactive protein increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TRASTUZUMAB. However, 173 reports have been filed with the FAERS database.

What Other Side Effects Does TRASTUZUMAB Cause?

Diarrhoea (4,996) Off label use (3,802) Nausea (3,499) Fatigue (3,417) Myelosuppression (2,552) Disease progression (2,449) Death (2,378) Vomiting (2,244) Dyspnoea (2,010) Pyrexia (1,886)

What Other Drugs Cause C-reactive protein increased?

METHOTREXATE (5,999) ADALIMUMAB (4,579) RITUXIMAB (4,060) ETANERCEPT (3,922) TOCILIZUMAB (3,719) INFLIXIMAB (3,621) LEFLUNOMIDE (3,574) HYDROXYCHLOROQUINE (3,552) ABATACEPT (3,451) SULFASALAZINE (3,096)

Which TRASTUZUMAB Alternatives Have Lower C-reactive protein increased Risk?

TRASTUZUMAB vs TRASTUZUMAB-ANNS TRASTUZUMAB vs TRASTUZUMAB DERUXTECAN TRASTUZUMAB vs TRASTUZUMAB-DKST TRASTUZUMAB vs TRASTUZUMAB-DTTB TRASTUZUMAB vs TRASTUZUMAB EMTANSINE

Related Pages

TRASTUZUMAB Full Profile All C-reactive protein increased Reports All Drugs Causing C-reactive protein increased TRASTUZUMAB Demographics